Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa Patent Verdict Coming April 14

This article was originally published in The Pink Sheet Daily

Executive Summary

Timing of the Indianapolis court's verdict suggests the outcome could be favorable for Lilly. The announcement comes a week after a federal appeals court rescinded a ruling on a Paxil patent that could have aided generic companies' challenges to the olanzapine patent.

You may also be interested in...



Lilly Zyprexa Patent Upheld On All Counts

The district court ruling means that generic versions of olanzapine are unlikely to enter the market before 2011, when the only "Orange Book" listed patent for Zyprexa is set to expire.

Lilly Zyprexa Patent Upheld On All Counts

The district court ruling means that generic versions of olanzapine are unlikely to enter the market before 2011, when the only "Orange Book" listed patent for Zyprexa is set to expire.

Kos Settlement Keeps Barr’s Generic Niaspan, Advicor Off Market Until 2013

The generic firm’s decision to settle appears to have been influenced by a federal appeals court’s recent decision to rescind an earlier ruling on “public use” and patent invalidity in the Paxil case. Barr could enter the market before 2013 if another ANDA product launches.

Related Content

Topics

UsernamePublicRestriction

Register

PS061987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel